Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.
More than 100,000 Americans died from diabetes in 2021, marking the second consecutive year for that grim milestone and spurring a call for a federal mobilization similar to the fight against HIV/AIDS.
The U.S. Food and Drug Administration approved Switzerland-based pharmaceutical company Roche’s HIV-1/HIV-2 qualitative test for use on the fully automated Cobas 6800/8800 Systems.
The U.S. Supreme Court ruled that a 2003 law does not violate constitutional free speech rights by requiring overseas affiliates of American-based nonprofit groups that seek federal funding for HIV/AIDS relief to take a formal stance opposing prostitution and sex trafficking.
Fingerpaint – a national full-service health and wellness marketing agency – in partnership with The Alliance for Positive Health, launched a provocative campaign aimed at bringing awareness to the alarming increase of sexually transmitted infections across the country.
With a Pharma Market Free of Rebates, We Can Sell on Value AgainBusiness, Cancer, Cardiovascular Disease, Consumers, CVS Health, Department of Health and Human Services (HHS), Drug Pricing, Drug Rebates, Drug Wholesalers, Drugs, Health Insurers, Health Outcomes, HIV/AIDS, Issue Archives, June 2019, Manufacturers, Pharma, Pharmacy Benefit Management (PBM) Business, Retail Pharmacies, Supply Chain
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
The U.S. FDA approved two of Merck & Co. Inc.’s HIV oral drugs nearly two months ahead of schedule.
The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed top-line data from the Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of the first investigational long-acting injectable two-drug regimen for the treatment of HIV-1.
A long-acting injection developed by GlaxoSmithKline and given once a month proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.